- Chatterjee A, Rodger EJ, Ahn A, Stockwell PA, Parry M, Motwani J, Gallagher SJ, Shklovskaya E, Tiffen J, Eccles MR, Hersey P: Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma. iScience 2018, 4:312-325.
- Chatterjee A, Ahn A, Rodger EJ, Stockwell PA, Eccles MR: A Guide for Designing and Analyzing RNA-Seq Data. Methods Mol Biol 2018, 1783:35-80.
- Ahn A, Chatterjee A, Eccles MR: The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma. Mol Cancer Ther 2017, 16:1002-1009.
- Chatterjee A, Stockwell PA, Ahn A, Rodger EJ, Leichter AL, Eccles MR: Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis. Oncotarget 2017, 8:6085-6101.
- Chatterjee A, Macaulay EC, Ahn A, Ludgate JL, Stockwell PA, Weeks RJ, Parry MF, Foster TJ, Knarston IM, Eccles MR, Morison IM: Comparative assessment of DNA methylation patterns between reduced representation bisulfite sequencing and Sequenom EpiTyper methylation analysis. Epigenomics 2017, 9:823-832.
- Jones AM, Ferguson P, Gardner J, Rooker S, Sutton T, Ahn A, Chatterjee A, Bickley VM, Sarwar M, Emanuel P, et al: NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand. Oncotarget 2016, 7:41017-41030.
- Royds JA, Pilbrow AP, Ahn A, Morrin HR, Frampton C, Russell IA, Moravec CS, Sweet WE, Tang WH, Currie MJ, et al: The rs11515 Polymorphism Is More Frequent and Associated With Aggressive Breast Tumors with Increased ANRIL and Decreased p16 (INK4a) Expression. Front Oncol 2015, 5:306.
- Ahn A, Eccles MR: Targeted therapy; from advanced melanoma to the adjuvant setting. Front Oncol 2013, 3:205.
- Eccles MR, He S, Ahn A, Slobbe LJ, Jeffs AR, Yoon HS, Baguley BC: MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a “Genetic Switch” Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma. Front Oncol 2013, 3:229.
- Royds JA, Al Nadaf S, Wiles AK, Chen YJ, Ahn A, Shaw A, Bowie S, Lam F, Baguley BC, Braithwaite AW, et al: The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS One 2011, 6:e26737.